©2022 Stanford Medicine
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Trial ID: NCT03142191
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response.
A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Subject understands and has voluntarily signed and dated an informed consent form
1. Subject is male or female ≥ 40 years of age
2. Diagnosis of IPF is supported by HRCT and historical lung biopsy (surgical lung biopsy
[SLB] or cryobiopsy) if available according to guidelines.
3. No features supporting an alternative diagnosis on transbronchial biopsy,
bronchoalveolar lavage (BAL), or SLB, if performed.
4. Percent predicted forced vital capacity (% FVC) ≥ 45% and ≤ 95% at Screening
5. Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and
≤ 90% predicted at Screening.
6. Able to walk ≥ 150 meters during the 6-minute walk test (6MWT) at Screening
7. Females of childbearing potential (FCBP) must commit to true abstinence or agree to
use two effective birth control methods.
8. Male subjects must practice true abstinence or use a barrier method of contraception.
9. Additional inclusion criteria apply.
Progressive Pulmonary Fibrosis (PPF) Sub-Study:
1. Met all inclusion criteria described for IPF subjects other than Inclusion Criterion
2. Features of diffuse fibrosing lung disease of > 10% on HRCT by central reading.
3. Investigator-documented ≥ 5% annualized relative decline in FVC in past 24 months from
Screening Visit 1
The presence of any of the following will exclude a subject from enrollment:
1. Subject has any significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study.
2. Subject with a QTcF > 450 msec.
3. Evidence of clinically relevant airways obstruction at Screening.
4. Subjects using therapy targeted to treat IPF.
5. History of latent or active TB, unless there is medical record documentation of
successful completion of a standard course of treatment
6. History of hepatitis B and/or hepatitis C, including those considered successfully
7. Pregnancy or lactation.
8. Additional exclusion criteria apply.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305